Literature DB >> 35491771

A pilot study to troubleshoot quality control metrics when assessing circulating miRNA expression data reproducibility across study sites.

Jennifer B Permuth1,2, Tania Mesa3, Sion L Williams4, Yoslayma Cardentey4, Dongyu Zhang5, Erica A Pawlak6, Jiannong Li7, Miles E Cameron8, Karla N Ali1, Daniel Jeong1,9, Sean J Yoder3, Dung-Tsa Chen7, Jose G Trevino10,11, Nipun Merchant12, Mokenge Malafa2.   

Abstract

BACKGROUND: Given the growing interest in using microRNAs (miRNAs) as biomarkers of early disease, establishment of robust protocols and platforms for miRNA quantification in biological fluids is critical.
OBJECTIVE: The goal of this multi-center pilot study was to evaluate the reproducibility of NanoString nCounter™ technology when analyzing the abundance of miRNAs in plasma and cystic fluid from patients with pancreatic lesions.
METHODS: Using sample triplicates analyzed across three study sites, we assessed potential sources of variability (RNA isolation, sample processing/ligation, hybridization, and lot-to-lot variability) that may contribute to suboptimal reproducibility of miRNA abundance when using nCounter™, and evaluated expression of positive and negative controls, housekeeping genes, spike-in genes, and miRNAs.
RESULTS: Positive controls showed a high correlation across samples from each site (median correlation coefficient, r> 0.9). Most negative control probes had expression levels below background. Housekeeping and spike-in genes each showed a similar distribution of expression and comparable pairwise correlation coefficients of replicate samples across sites. A total of 804 miRNAs showed a similar distribution of pairwise correlation coefficients between replicate samples (p= 0.93). After normalization and selecting miRNAs with expression levels above zero in 80% of samples, 55 miRNAs were identified; heatmap and principal component analysis revealed similar expression patterns and clustering in replicate samples.
CONCLUSIONS: Findings from this pilot investigation suggest the nCounter platform can yield reproducible results across study sites. This study underscores the importance of implementing quality control procedures when designing multi-center evaluations of miRNA abundance.

Entities:  

Keywords:  MiRNA quantitation; biomarkers; biospecimens; pancreatic cancer; reproducibility

Mesh:

Substances:

Year:  2022        PMID: 35491771      PMCID: PMC9428925          DOI: 10.3233/CBM-210255

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   3.828


  16 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

2.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples.

Authors:  Yaguang Xi; Go Nakajima; Elaine Gavin; Chris G Morris; Kenji Kudo; Kazuhiko Hayashi; Jingfang Ju
Journal:  RNA       Date:  2007-08-13       Impact factor: 4.942

Review 3.  Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples.

Authors:  Margaret H Veldman-Jones; Roz Brant; Claire Rooney; Catherine Geh; Hollie Emery; Chris G Harbron; Mark Wappett; Alan Sharpe; Michael Dymond; J Carl Barrett; Elizabeth A Harrington; Gayle Marshall
Journal:  Cancer Res       Date:  2015-06-11       Impact factor: 12.701

4.  Partnering to advance early detection and prevention efforts for pancreatic cancer: the Florida Pancreas Collaborative.

Authors:  Jennifer B Permuth; Jose Trevino; Nipun Merchant; Mokenge Malafa
Journal:  Future Oncol       Date:  2016-02-10       Impact factor: 3.404

5.  MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Authors:  Nicolai A Schultz; Christian Dehlendorff; Benny V Jensen; Jon K Bjerregaard; Kaspar R Nielsen; Stig E Bojesen; Dan Calatayud; Svend E Nielsen; Mette Yilmaz; Niels Henrik Holländer; Klaus K Andersen; Julia S Johansen
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

6.  Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.

Authors:  Colin C Pritchard; Evan Kroh; Brent Wood; Jason D Arroyo; Katy J Dougherty; Melanie M Miyaji; Jonathan F Tait; Muneesh Tewari
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-12

7.  Circulating microRNAs as stable blood-based markers for cancer detection.

Authors:  Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

Review 8.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

9.  MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Nir Lubezky; Shelly Loewenstein; Menahem Ben-Haim; Eli Brazowski; Sylvia Marmor; Metsada Pasmanik-Chor; Varda Oron-Karni; Gideon Rechavi; Joseph M Klausner; Guy Lahat
Journal:  Surgery       Date:  2013-01-07       Impact factor: 3.982

10.  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.

Authors:  Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.